Texas Oncology-Waco

Waco, Texas 76712

1 studies enrolling now · 16 studies all time

What they study most

Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Adenocarcinoma of the Lung, Anemia, Refractory, With Excess of Blasts, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer, Breast Neoplasms, Cancer, GIST, Locally Advanced Renal Cell Carcinoma, Locally Advanced Urothelial Cancer

Studies at this site

• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
• Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) — Completed
• A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer — Running, not enrolling
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) — Status unconfirmed
• Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile — Completed
• A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer — Completed
• ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients — Completed
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) — Completed
• A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations — Completed
• (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST — Completed
• An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread — Completed
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung — Completed
• ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer — Completed
• Ixabepilone + Carboplatin Metastatic Breast Cancer — Completed
• Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies — Completed